Evidence, national guidance and prescribing practice during the first COVID-19 wave in Uzbekistan: an interrupted time-series analysis of 2433 hospital admissions

Written guidance is the usual instrument for moving new evidence into practice, but its contribution is rarely measurable, because prescribing data and dated guideline texts are seldom available together. Uzbekistan’s first COVID-19 wave provides both. We measured when prescribing changed relative to international evidence and to dated national guidance; we did not measure the mechanisms by which either reached the ward. Interrupted time-series analysis of all 2433 patients admitted to a designated COVID-19 hospital in Tashkent between 11 April and 10 August 2020, linked to the dated national interim guidance in force. For dexamethasone, anticoagulants, hydroxychloroquine, azithromycin and any antibiotic (a prespecified negative control), change points were located at daily resolution by profile likelihood with bootstrap intervals, and segmented logistic regression was fitted with adjustment for age, sex, comorbidity, severity and asymptomatic status. Patients are located in time by admission date. Among patients admitted from 16 June 2020, the day the RECOVERY result was announced, dexamethasone prescribing rose from 1.1% to 54.3%, reaching 77.1% while the guidance in force advised against routine corticosteroids. Hydroxychloroquine and azithromycin did not change at the WHO announcement of 17 June − 90.0% of patients admitted in the following four weeks still received hydroxychloroquine - and changed among patients admitted from 20 July, seven days after national withdrawal took effect (hydroxychloroquine 91.1% to 16.2%; azithromycin 93.6% to 44.8%). When guidance reinstated hydroxychloroquine on 31 July, prescribing did not return (5.3%). Anticoagulation, recommended nationally since March, changed only from 15 July (8.7% to 76.6%). The negative control did not change. Evidence, national guidance and prescribing practice moved on markedly different timelines for adoption, de-adoption and attempted re-adoption within one hospital. De-adoption was temporally associated with national withdrawal rather than with the international evidence; adoption of dexamethasone preceded and for a period ran against the guidance in force; reinstatement was not followed. The organizational mechanisms behind these differences - who decided, what authority guidance carried, how it reached the ward - were not measured and are the priority for future work.

Authors

Institutions

Publication Details

Journal
Implementation Science Communications
Published
2026-11-19
DOI
https://doi.org/10.1186/s43058-026-01179-4
Primary Topic
Clinical practice guidelines implementation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evidence, national guidance and prescribing practice during the first COVID-19 wave in Uzbekistan: an interrupted time-series analysis of 2433 hospital admissions

Alisher Shadmanov, Laziz Nadirovich Tuychiev, Bakhodir B. Rakhimov, Kyung-Hee Kim et al.
Implementation Science Communications
Clinical practice guidelines implementation
article

Evidence, national guidance and prescribing practice during the first COVID-19 wave in Uzbekistan: an interrupted time-series analysis of 2433 hospital admissions

Alisher Shadmanov, Laziz Nadirovich Tuychiev, Bakhodir B. Rakhimov, Kyung-Hee Kim, Kurbaniyazova Malika Oralbayevna, Jaewook Choi, Nilufar Khamzaeva
article en

Abstract

Written guidance is the usual instrument for moving new evidence into practice, but its contribution is rarely measurable, because prescribing data and dated guideline texts are seldom available together. Uzbekistan’s first COVID-19 wave provides both. We measured when prescribing changed relative to international evidence and to dated national guidance; we did not measure the mechanisms by which either reached the ward. Interrupted time-series analysis of all 2433 patients admitted to a designated COVID-19 hospital in Tashkent between 11 April and 10 August 2020, linked to the dated national interim guidance in force. For dexamethasone, anticoagulants, hydroxychloroquine, azithromycin and any antibiotic (a prespecified negative control), change points were located at daily resolution by profile likelihood with bootstrap intervals, and segmented logistic regression was fitted with adjustment for age, sex, comorbidity, severity and asymptomatic status. Patients are located in time by admission date. Among patients admitted from 16 June 2020, the day the RECOVERY result was announced, dexamethasone prescribing rose from 1.1% to 54.3%, reaching 77.1% while the guidance in force advised against routine corticosteroids. Hydroxychloroquine and azithromycin did not change at the WHO announcement of 17 June − 90.0% of patients admitted in the following four weeks still received hydroxychloroquine - and changed among patients admitted from 20 July, seven days after national withdrawal took effect (hydroxychloroquine 91.1% to 16.2%; azithromycin 93.6% to 44.8%). When guidance reinstated hydroxychloroquine on 31 July, prescribing did not return (5.3%). Anticoagulation, recommended nationally since March, changed only from 15 July (8.7% to 76.6%). The negative control did not change. Evidence, national guidance and prescribing practice moved on markedly different timelines for adoption, de-adoption and attempted re-adoption within one hospital. De-adoption was temporally associated with national withdrawal rather than with the international evidence; adoption of dexamethasone preceded and for a period ran against the guidance in force; reinstatement was not followed. The organizational mechanisms behind these differences - who decided, what authority guidance carried, how it reached the ward - were not measured and are the priority for future work.

Implementation Science Communications
Korea University (KR), Ministry of Health of the Republic of Uzbekistan (UZ), Korea University (JP), Tashkent Pediatric Medical Institute (UZ)
Clinical practice guidelines implementation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon